General Catalyst
Edit

General Catalyst

https://www.generalcatalyst.com
Last activity: 21.03.2025
Active
Invests in categories: PlatformFinTechHealthTechDataSoftwareTechnologyServiceSecurityBusinessIT
General Catalyst is a venture capital firm that makes early-stage and transformational investments. General Catalyst backs exceptional entrepreneurs who are building innovative technology companies and market leading businesses, including Airbnb, BigCommerce, ClassPass, Datalogix, Datto, Demandware, Gusto (fka ZenPayroll), The Honest Company, HubSpot, KAYAK, Oscar, Snap, Stripe, and Warby Parker. The General Catalyst team leverages its broad experience to help founders build extraordinary companies. General Catalyst has offices in Cambridge, MA, Palo Alto, CA and New York City.

For more information, visit: www.generalcatalyst.com.
Likes
3.09K
Portfolio
319
Mentions
1.06K
Location: United States, Massachusetts, Cambridge
Employees: 51-200
Founded date: 2000
Investment Type: Venture Capital
Investment Stage: Pre-Seed; Seed; Series A; Series B; Series C; Series D; Series E

Portfolio 319

DateNameWebsiteTotal RaisedLocation
11.03.2025Podqipodqi.com$3.2M-
13.02.2025Eudiaeudia.com$105M-
28.01.2025Onebriefonebrief.com$156MUnited Sta...
26.11.2024Medeloopmedeloop.ai$23.5MUnited Sta...
18.11.2024Goodstackgoodstack.io$28M-
15.11.2024Lean Techn...leantech.me$67.5MSaudi Arab...
16.10.2024autoneautone.io$23.22MUnited Kin...
09.10.2024Rippl Careripplcare.com$58MUnited Sta...
01.10.2024Nurix AInurix.ai$27.5M-
30.08.2024Codeiumcodeium.com$215MUnited Sta...
Show more

Mentions in press and media 1060

DateTitleDescription
21.03.2025Crescendo's Leap into the Future of Customer Experience with Agentic AIIn the bustling world of customer service, Crescendo is making waves. The company has unveiled a powerful expansion of its augmented AI platform, introducing agentic AI capabilities. This leap is not just a step; it’s a giant leap for custo...
21.03.2025Crescendo Expands its Platform for CX with Agentic AICrescendo, pioneers of Augmented AI, today announced that it has expanded its fully managed augmented AI platform with new agentic AI capabilities to automate more tasks and a new conversational CX Data Assistant that provides strategic ins...
20.03.2025Crescendo Expands its Platform for CX with Agentic AICrescendo, pioneers of Augmented AI, announced that it has expanded its fully managed augmented AI platform with new agentic AI capabilities to automate more tasks and a new conversational CX Data Assistant that provides strategic insights ...
19.03.2025More funding for Factorial – the Spanish unicorn bags an additional €110 millionFactorial, a Barcelona-based business management software, today announced a €110 million expansion of its investment agreement with General Catalyst, increasing the total investment from €73 million to €183 million. The new funding will fu...
18.03.2025Maxion Therapeutics: A New Dawn in Biotech InnovationIn the heart of Cambridge, a biotech revolution is brewing. Maxion Therapeutics has just secured €68.9 million in a Series A funding round, marking a significant milestone in the quest for innovative therapies. This funding, led by General ...
18.03.2025Maxion Therapeutics: £58 Million (Series A) Closed For Developing KnotBody Drugs For Ion Channel- And GPCR-Driven DiseasesMaxion Therapeutics, a biotechnology company developing antibody-based KnotBody drugs for ion channel- and G protein-coupled receptor (GPCR)-driven diseases, announced that it has raised $72 million (£58 million) in a Series A financing. Th...
17.03.2025Biotech Maxion Therapeutics secures $72M Series ACambridge-based Maxion Therapeutics, a biotech developing antibody-based drugs for ion channel- and G protein coupled receptor (GPCR)-driven diseases, has raised $72M in a Series A round. The round was led by General Catalyst with additiona...
17.03.2025Maxion Therapeutics Raises $72M in Series A FundingMaxion Therapeutics, a Cambridge, UK-based biotechnology company developing antibody-based KnotBody® drugs for ion channel- and G protein coupled receptor (GPCR)-driven diseases, raised $72M (£58M) in Series A funding. The round was led by ...
17.03.2025Maxion Therapeutics raises €68 million to advance its KnotBody pipeline and platformCambridge-based Maxion Therapeutics, a BioTech company developing antibody-based KnotBody drugs for ion channel and G protein coupled receptor (GPCR) driven diseases, announced today that it has raised €68.9 million in a Series A financing....
15.03.2025PepsiCo's Bold Move: Acquiring Poppi and the Rise of Functional BeveragesPepsiCo is making waves in the beverage industry. The giant is in advanced talks to acquire Poppi, a healthier soda brand, for over $1.5 billion. This move is not just about expanding its portfolio; it’s a strategic pivot towards health-con...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In